Omura

Omura X Releaf Omura are excited to announce the extension of our strategic partnership with Releaf, moving into 2025, we will continue to supply Omura devices direct to UK patients, exclusively through Releaf. We began talks of a partnership at the beginning of 2024 with Tim Kirby, CEO, at Releaf; this was in the context of Omura seeking distribution partners in the UK Medical Cannabis sector for our newly released Series X device and Home Filling System. Having conducted an in-depth study of the UK Medical Cannabis Clinics, we sought out a partner that put the patient first and was focused on meeting the unmet healthcare needs of millions of UK adults. Releaf stood out from the first meeting, why?? There were X3 key fundamentals that made Releaf a clear winner for Omura: Quality of leadership: From CEO Tim Kirby’s stellar track record of leading rapid growth in complex, highly-regulated sectors, through to COO, Graham Woodward’s role as a Specialist Advisor to the CQC (Care Quality Commission), the breadth and depth in the quality of leadership at Releaf was clear. Rupa Shah, Releaf’s Compliance Director, also sits on committees within the ASA, ensuring expert insight on how to go to market in a fully compliant manner - a task that is not easy within this highly regulated sector. Releaf's Senior Leadership Team’s commitment to adhering to a set of rigorous prescribing guidelines and quality guarantees contained within their Patient Charter, was unrivalled when compared with other clinics. Commercial Confidence: The incumbent providers in the UK have all failed to gain any meaningful scale and are at the root cause of the sector's stagnation since legislation changes in 2018 to allow the prescribing of Medical Cannabis. The total addressable market in the UK is c. 3M (based on 3% of adults holding a prescription in a mature market, as opposed to the current mere c. 30,000 in the UK); Releaf was the only clinic we met with who could demonstrate a fully-integrated proprietary HealthTech platform and a proven digital marketing approach capable of supporting the ability to go to market at scale. Releaf’s forecasts are met consistently, and their 26 doctors are now seeing upwards of approaching 200 patients/day, all of whom are now able to enjoy the experience and benefits of our best in class? Series X Omura device following their Treatment Plans. Streamlining the Supply Chain: Lack of consistency and quality of supply has plagued UK patients. It was clear to us that Releaf had uniquely secured vertical integration across a range of providers, including the first UK-grown CBPMs from Glass Pharms in Wiltshire, with certain products only available through Releaf. This further highlighted how Releaf is strategically-positioned in the UK CBPM sector to redefine the market. We are pleased to say that Releaf has exceeded our expectations on all fronts and it is a pleasure to be extending this exclusive, strategic partnership.

Thanks for the review Cannabis Tech!

Omura is very proud to be launching this collaboration with Blutezeit at the Mary Jane show in Berlin this weekend https://lnkd.in/gpmy8ghz

Omura is at Mary Jane in Berlin! Come and see us at Stand D49 - “The only vaporizer that doesn't need cleaning!”

Just aired podcast of me talking about Revolutionizing the way we vaporize dry herbs with Omura on iHeart Radio Cannabis Talk 101 https://lnkd.in/gJvWpNuB